Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics

Evolus Inc. (NASDAQ:EOLS) is one of the stocks that will double in 2026. On December 2, Mizuho lowered the firm’s price target on Evolus to $19 from $20, while keeping an Outperform rating on the shares. Mizuho lowered its estimates for Evolus’s products, Jeuveau and Evolysse, due to the recent decline in consumer sentiment. The firm now expects a higher probability of sustained inflationary pressure negatively impacting demand for elective injectable facial aesthetic procedures. Despite this headwind, Mizuho believes that Evolus still possesses long-term prospects.

Earlier in its Q3 2025 earnings report, Evolus achieved global net revenue of $69 million, which marked a 13% increase year-over-year. This growth was fueled by robust global demand for its flagship neurotoxin, Jeuveau, which generated $63.2 million in revenue, and early contributions from the new Hyaluronic Acid/HA filler, Evolysse, which brought in $5.7 million in the quarter. For the full year 2025, Evolus updated its total net revenue outlook, projecting figures between $295 and $305 million.

Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics

Evolus reinforced its market position and achieved a 14% market share in the US aesthetic neurotoxin market. The customer loyalty program is a key driver of engagement, having grown to over 1.3 million members, which represented a 34% year-on-year increase. The company also expanded its professional customer base, adding ~500 new purchasing accounts in Q3. Despite these positive indicators, the US aesthetic market faces ongoing challenges related to consumer spending, and the HA filler market, in particular, is down by double-digits, creating a difficult environment for Evolysse’s strong debut.

Evolus Inc. (NASDAQ:EOLS) is a performance beauty company that delivers products in the cash-pay aesthetic market in the US, Canada, Europe, and Australia.

While we acknowledge the potential of EOLS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EOLS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.